RxDoctor Payments Data

Patrice Eglinton, DO

Family Medicine · Wilmington, NCNPI 1033572201

Payments from drug & device makers

$578in general payments, 2019–2025

Across 10 payments — averaging $57.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$349
  • Daiichi Sankyo Inc.$125
  • AbbVie$56
  • Medtronic$20
  • Biohaven Pharmaceutical Holding Company Ltd.$15
  • Otsuka America Pharmaceutical, Inc.$13

What the payments were for

  • Food & beverage$578100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$578 in reported general payments places this provider in the 60th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$173,191
Medicare patients
289
Services billed
5,437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin33$38,663
EliquisApixaban21$31,067
OzempicSemaglutide23$30,716
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$19,506
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$14,072
XareltoRivaroxaban17$12,841
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$10,074
Atorvastatin Calcium304$3,275
Albuterol Sulfate HfaAlbuterol Sulfate56$2,507
Rosuvastatin Calcium161$2,411
Levothyroxine Sodium196$2,238
Metoprolol Succinate110$2,046
Losartan Potassium158$1,844
Amlodipine Besylate225$1,594
Pantoprazole Sodium109$1,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$349$30,71623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →